NeuroPace (NPCE) Stock Forecast, Price Target & Predictions
NPCE Stock Forecast
NeuroPace stock forecast is as follows: an average price target of $12.88 (represents a 73.35% upside from NPCE’s last price of $7.43) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
NPCE Price Target
The average price target for NeuroPace (NPCE) is $12.88 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $5.50. This represents a potential 73.35% upside from NPCE's last price of $7.43.
NPCE Analyst Ratings
According to 5 Wall Street analysts, NeuroPace's rating consensus is 'Buy'. The analyst rating breakdown for NPCE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 2 'Hold' (40.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
NeuroPace Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Vik Chopra | Wells Fargo | $15.00 | $7.28 | 106.04% | 101.88% |
| May 23, 2024 | Frank Takkinen | Lake Street | $20.00 | $7.99 | 150.31% | 169.18% |
| Mar 14, 2024 | Larry Biegelsen | Wells Fargo | $20.00 | $13.63 | 46.74% | 169.18% |
| Nov 10, 2023 | Ross Osborn | Cantor Fitzgerald | $11.00 | $7.85 | 40.13% | 48.05% |
| Jul 15, 2022 | - | Morgan Stanley | $5.50 | $5.74 | -4.18% | -25.98% |
| May 13, 2022 | - | Morgan Stanley | $6.00 | $5.96 | 0.67% | -19.25% |
The latest NeuroPace stock forecast, released on Aug 14, 2024 by Vik Chopra from Wells Fargo, set a price target of $15.00, which represents a 106.04% increase from the stock price at the time of the forecast ($7.28), and a 101.88% increase from NPCE last price ($7.43).
NeuroPace Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $15.00 | $16.50 |
| Last Closing Price | $7.43 | $7.43 | $7.43 |
| Upside/Downside | -100.00% | 101.88% | 122.07% |
In the current month, the average price target of NeuroPace stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NeuroPace's last price of $7.43. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 29, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Mar 14, 2024 | Wells Fargo | Buy | Overweight | Upgrade |
| Feb 22, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jan 30, 2024 | Lake Street | Underperform | Underperform | Hold |
| Jan 30, 2024 | Leerink Partners | Buy | Buy | Hold |
| Dec 27, 2023 | Wells Fargo | Buy | Buy | Hold |
| Feb 22, 2023 | Piper Sandler | - | Neutral | Initialise |
| Feb 22, 2023 | Cowen & Co. | - | Neutral | Initialise |
| Feb 22, 2023 | Lake Street | - | Buy | Initialise |
NeuroPace's last stock rating was published by Wells Fargo on Aug 14, 2024. The company gave NPCE a "Overweight" rating, the same as its previous rate.
NeuroPace Financial Forecast
NeuroPace Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $16.43M | $16.51M | $14.47M | $12.79M | $11.16M | $10.20M | $11.37M | $11.00M | $10.34M | $12.63M | $11.22M |
| Avg Forecast | $24.30M | $22.90M | $21.70M | $20.35M | $20.73M | $19.07M | $18.30M | $17.33M | $17.41M | $14.22M | $12.63M | $12.18M | $12.40M | $9.90M | $11.08M | $10.64M | $11.00M | $10.80M | $11.17M | $10.98M |
| High Forecast | $24.87M | $23.44M | $22.21M | $20.83M | $21.22M | $19.40M | $18.73M | $17.74M | $17.82M | $14.56M | $12.92M | $12.46M | $12.69M | $10.13M | $11.31M | $10.86M | $11.23M | $11.02M | $11.40M | $11.21M |
| Low Forecast | $23.94M | $22.56M | $21.38M | $20.05M | $20.43M | $18.53M | $18.03M | $17.08M | $17.15M | $14.02M | $12.44M | $12.00M | $12.22M | $9.75M | $10.84M | $10.42M | $10.77M | $10.57M | $10.93M | $10.75M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.15% | 1.31% | 1.19% | 1.03% | 1.13% | 0.92% | 1.07% | 1.00% | 0.96% | 1.13% | 1.02% |
NeuroPace's average Quarter revenue forecast for Dec 23 based on 3 analysts is $17.41M, with a low forecast of $17.15M, and a high forecast of $17.82M. NPCE's average Quarter revenue forecast represents a 5.98% increase compared to the company's last Quarter revenue of $16.43M (Sep 23).
NeuroPace EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-5.95M | $-7.85M | $-8.02M | $-9.21M | $-9.14M | $-10.09M | $-8.88M | $-8.94M | $-6.18M | $-6.55M | $-6.89M |
| Avg Forecast | $-13.29M | $-12.52M | $-11.86M | $-11.13M | $-11.34M | $-10.43M | $-10.00M | $-9.48M | $-9.52M | $-7.78M | $-6.90M | $-6.66M | $-6.78M | $-6.78M | $-6.06M | $-8.27M | $-6.01M | $-5.91M | $-7.06M | $-6.00M |
| High Forecast | $-13.09M | $-12.34M | $-11.69M | $-10.96M | $-11.17M | $-10.13M | $-9.86M | $-9.34M | $-9.38M | $-7.66M | $-6.80M | $-6.56M | $-6.68M | $-5.42M | $-5.93M | $-6.62M | $-5.89M | $-5.78M | $-5.65M | $-5.88M |
| Low Forecast | $-13.60M | $-12.82M | $-12.14M | $-11.39M | $-11.60M | $-10.61M | $-10.24M | $-9.70M | $-9.74M | $-7.96M | $-7.07M | $-6.81M | $-6.94M | $-8.13M | $-6.18M | $-9.93M | $-6.14M | $-6.03M | $-8.47M | $-6.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.14% | 1.20% | 1.36% | 1.35% | 1.67% | 1.07% | 1.49% | 1.05% | 0.93% | 1.15% |
undefined analysts predict NPCE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NeuroPace's previous annual EBITDA (undefined) of $NaN.
NeuroPace Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-7.26M | $-9.12M | $-14.40M | $-12.43M | $-13.37M | $-14.41M | $-13.16M | $-8.83M | $-8.08M | $-8.49M | $-8.81M |
| Avg Forecast | $-5.96M | $-6.73M | $-7.41M | $-7.79M | $-7.21M | $-7.75M | $-8.66M | $-9.27M | $-9.09M | $-11.66M | $-13.56M | $-13.20M | $-14.43M | $-8.86M | $-12.98M | $-10.68M | $-9.52M | $-8.77M | $-9.15M | $-6.83M |
| High Forecast | $-5.85M | $-6.60M | $-7.26M | $-7.64M | $-7.08M | $-7.15M | $-8.49M | $-9.09M | $-8.26M | $-11.43M | $-13.30M | $-12.95M | $-14.15M | $-7.09M | $-12.62M | $-8.54M | $-9.26M | $-8.53M | $-7.32M | $-6.64M |
| Low Forecast | $-6.15M | $-6.94M | $-7.63M | $-8.03M | $-7.43M | $-8.05M | $-8.92M | $-9.55M | $-9.91M | $-12.01M | $-13.98M | $-13.61M | $-14.87M | $-10.63M | $-13.33M | $-12.82M | $-9.78M | $-9.01M | $-10.98M | $-7.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.62% | 0.67% | 1.09% | 0.86% | 1.51% | 1.11% | 1.23% | 0.93% | 0.92% | 0.93% | 1.29% |
NeuroPace's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NPCE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NeuroPace SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $13.39M | $14.48M | $13.43M | $13.57M | $12.55M | $12.77M | $12.44M | - | $9.42M | $9.53M | $8.27M |
| Avg Forecast | $20.96M | $19.75M | $18.71M | $17.55M | $17.88M | $16.44M | $15.78M | $14.94M | $15.01M | $12.27M | $10.89M | $10.50M | $10.69M | $8.54M | $9.56M | $9.18M | $9.49M | $9.31M | $10.26M | $9.47M |
| High Forecast | $21.45M | $20.21M | $19.16M | $17.96M | $18.30M | $16.73M | $16.15M | $15.30M | $15.37M | $12.56M | $11.14M | $10.75M | $10.95M | $8.74M | $9.75M | $9.37M | $9.68M | $9.51M | $12.31M | $9.66M |
| Low Forecast | $20.65M | $19.46M | $18.44M | $17.29M | $17.62M | $15.98M | $15.55M | $14.73M | $14.79M | $12.09M | $10.73M | $10.35M | $10.54M | $8.41M | $9.35M | $8.98M | $9.28M | $9.12M | $8.21M | $9.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.09% | 1.33% | 1.28% | 1.27% | 1.47% | 1.34% | 1.36% | - | 1.01% | 0.93% | 0.87% |
NeuroPace's average Quarter SG&A projection for Dec 23 is $15.01M, based on 3 Wall Street analysts, with a range of $14.79M to $15.37M. The forecast indicates a 12.14% rise compared to NPCE last annual SG&A of $13.39M (Sep 23).
NeuroPace EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.28 | $-0.36 | $-0.57 | $-0.50 | $-0.54 | $-0.59 | $-0.54 | $-0.37 | $-0.34 | $-0.48 | $-0.40 |
| Avg Forecast | $-0.21 | $-0.23 | $-0.26 | $-0.27 | $-0.25 | $-0.27 | $-0.30 | $-0.32 | $-0.31 | $-0.40 | $-0.47 | $-0.46 | $-0.50 | $-0.53 | $-0.45 | $-0.44 | $-0.33 | $-0.30 | $-0.34 | $-0.24 |
| High Forecast | $-0.20 | $-0.23 | $-0.25 | $-0.26 | $-0.25 | $-0.25 | $-0.29 | $-0.32 | $-0.29 | $-0.40 | $-0.46 | $-0.45 | $-0.49 | $-0.52 | $-0.44 | $-0.43 | $-0.32 | $-0.30 | $-0.33 | $-0.23 |
| Low Forecast | $-0.21 | $-0.24 | $-0.26 | $-0.28 | $-0.26 | $-0.28 | $-0.31 | $-0.33 | $-0.34 | $-0.42 | $-0.48 | $-0.47 | $-0.52 | $-0.54 | $-0.46 | $-0.45 | $-0.34 | $-0.31 | $-0.34 | $-0.24 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.69% | 0.77% | 1.25% | 1.00% | 1.02% | 1.31% | 1.22% | 1.12% | 1.12% | 1.43% | 1.67% |
According to undefined Wall Street analysts, NeuroPace's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NPCE previous annual EPS of $NaN (undefined).
NeuroPace Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVRO | Nevro | $5.79 | $32.99 | 469.78% | Hold |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| IRMD | IRadimed | $48.47 | $60.00 | 23.79% | Buy |
| AORT | Artivion | $25.25 | $30.00 | 18.81% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
| GKOS | Glaukos | $126.28 | $101.56 | -19.58% | Buy |
NPCE Forecast FAQ
Is NeuroPace a good buy?
Yes, according to 5 Wall Street analysts, NeuroPace (NPCE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of NPCE's total ratings.
What is NPCE's price target?
NeuroPace (NPCE) average price target is $12.88 with a range of $5.5 to $20, implying a 73.35% from its last price of $7.43. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NeuroPace stock go up soon?
According to Wall Street analysts' prediction for NPCE stock, the company can go up by 73.35% (from the last price of $7.43 to the average price target of $12.88), up by 169.18% based on the highest stock price target, and down by -25.98% based on the lowest stock price target.
Can NeuroPace stock reach $11?
NPCE's average twelve months analyst stock price target of $12.88 supports the claim that NeuroPace can reach $11 in the near future.
What are NeuroPace's analysts' financial forecasts?
NeuroPace's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $75.43M (high $77.09M, low $74.07M), average EBITDA is $-41.241M (high $-40.498M, low $-42.151M), average net income is $-32.889M (high $-31.813M, low $-33.958M), average SG&A $65.05M (high $66.48M, low $63.87M), and average EPS is $-1.14 (high $-1.103, low $-1.177). NPCE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $89.25M (high $91.35M, low $87.94M), average EBITDA is $-48.799M (high $-48.083M, low $-49.95M), average net income is $-27.892M (high $-27.359M, low $-28.747M), average SG&A $76.97M (high $78.78M, low $75.84M), and average EPS is $-0.967 (high $-0.948, low $-0.996).
Did the NPCE's actual financial results beat the analysts' financial forecasts?
Based on NeuroPace's last annual report (Dec 2023), the company's revenue was $65.42M, beating the average analysts forecast of $56.43M by 15.93%. Apple's EBITDA was $-27.174M, missing the average prediction of $-30.856M by -11.93%. The company's net income was $-32.956M, missing the average estimation of $-47.506M by -30.63%. Apple's SG&A was $54.52M, beating the average forecast of $48.67M by 12.02%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.646 by -99.92%. In terms of the last quarterly report (Sep 2023), NeuroPace's revenue was $16.43M, beating the average analysts' forecast of $14.22M by 15.48%. The company's EBITDA was $-5.95M, missing the average prediction of $-7.778M by -23.50%. NeuroPace's net income was $-7.257M, missing the average estimation of $-11.657M by -37.74%. The company's SG&A was $13.39M, beating the average forecast of $12.27M by 9.13%. Lastly, the company's EPS was $-0.28, missing the average prediction of $-0.404 by -30.69%